NCT01033422 - Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

December 31, 2016

Study Completion Date

April 30, 2017

Conditions

Ocular HypertensionGlaucoma

Interventions

DRUG

CF101

CF101 1 or 2 mg tablets orally every 12 hours for 16 weeks

DRUG

Placebo for

Matching placebo tablets orally every 12 hours for 16 weeks

Trial Locations (3)

"Specialized Hospital for Active Treatment for Eye Diseases Zrenie", Sofia

"University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna - ISUL", Sofia

Bnei Zion Medical Center, Haifa